Seed funding

#Biotech #Financing #mRNA #Seed funding

Biotech raises a €31.5m seed round to develop mRNA therapeutics

SRTD Biotech has announced the successful completion of an oversubscribed €31.5 million seed financing round.   The financing was led by Mérieux Equity Partners, with NRW.BANK and Boehringer Ingelheim Venture Fund joining the syndicate as co-leads. Lilly Ventures, HTGF, and the Freiburg-based family Office Anobis Asset also participated in the seed… Read More

#Business & Investment #News #Start-up Zone

#ALLOX #Artificial intelligence (AI) #Drug discovery #Financing #Seed funding

ALLOX closes $10.5m financing to scale allosteric discovery platform

ALLOX has announced the successful closing of its $10.5 million (€9.4m) seed financing round and the appointment of Morten Graugaard as Independent Chair of its Board of Directors.   The round was led by Asabys, through its Sabadell Asabys II fund, with participation from CDTI with its SICC Innvierte and the… Read More

#Business & Investment #News #Start-up Zone

siRNA
#Biotechnology platform #Eleven Therapeutics #Seed funding #siRNA #Therapeutics #Undecimal Bio

Seed financing to address ‘liver trap’ in siRNA therapeutic delivery 

Undecimal Bio, a platform biotechnology company advancing targeted delivery of siRNA therapeutics, has announced an oversubscribed $18 million seed financing.   The company is a spin-out from Eleven Therapeutics and will use the funding to expand DELiveri, its AI-enabled platform for identifying conjugates that can direct RNA… Read More

#News

#Artificial intelligence (AI) #Cambridge Crystallographic Data Centre #CCDC #CCDC Innovation Fund #Seed funding #Structural chemistry

CCDC launches Innovation Fund  

The Cambridge Crystallographic Data Centre (CCDC) has launched the CCDC Innovation Fund, a new seed funding programme designed to support emerging companies developing innovative solutions in structural chemistry.  The fund, backed by an initial commitment from the CCDC of up to £300,000, will provide early-stage support to start-ups and university spin-outs seeking to transform structural… Read More

#News

Protein degradation
#Protein degradation #Seed funding #TRIMTECH Therapeutics

TRIMTECH raises $47m for protein degradation portfolio 

TRIMTECH Therapeutics has raised an additional $14 million in seed funding, bringing total investment for the company’s targeted protein degradation portfolio to $47 million.  TRIMTECH has demonstrated its TRIMTAC and TRIMGLUE degraders can selectively degrade toxic protein aggregates and oligomers while leaving the functional monomeric forms of these proteins intact to… Read More

#Business & Investment #News

#Alys Pharmaceuticals #Atopic dermatitis #Biotechnology #Cold Urticaria #Dermatology #Drug discovery #Mastocytosis #Seed funding #Systemic mastocytosis

New podcast: First-in-class mechanisms for the next wave of dermatology innovation

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Thibaud Portal, Founder… Read More

#News

Seed fund
#Artificial intelligence (AI) #Drug discovery #Genetics / genomics #OutSee #Seed funding #Start-ups

Predictive genomics pioneer OutSee raises £1.8m

OutSee has secured £1.8 ($2.4) million in seed funding, led by Ahren Innovation Capital and with additional investment from Kadmos Capital, Empirical Ventures and Panacea Ventures.   The funds will support OutSee through the next phase of its growth strategy, with a focus on expanding the company’s in-house target discovery programme… Read More

#Business & Investment #News #Start-up Zone

Seed fund
#Funding #Obesity #Seed funding #Start-ups #University of Michigan #Weight loss

Weight loss start-up secures $7.8m investment

University of Michigan (U-M) spinout company Courage Therapeutics has received a seed investment of up to $7.8 million from Arsenal Bridge Ventures.  The investment will enable Courage Therapeutics to complete essential testing and development to advance its drug candidates to clinical trials.   The company’s two drug development programmes aim to… Read More

#Business & Investment #News #Start-up Zone

Ageing hands
#Ageing #Healthspan #Junevity #Seed funding #siRNA #Transcriptomics

Biotech raises $10m to address ageing at a cellular level

Junevity, a biotechnology company hoping to extend lifespan and healthspan by resetting cell damage from age-related diseases, has announced $10 million in seed funding led by Goldcrest Capital and Godfrey Capital.  The Junevity RESET platform is based on exclusively licensed research by co-founder Dr Janine Sengstack at the University of… Read More

#Business & Investment #News

RNA strand
#Akribion Therapeutics #Oncology #RNA #Seed funding #Start-ups

€8m financing to pioneer RNA-guided cell depletion 

Akribion Therapeutics has exited stealth mode and completed a seed financing round, raising €8 million to accelerate the development of novel therapeutics.  The round was led by CARMA FUND and RV Invest, with investments from MP Beteiligungs, Hessen Kapital I, Bruker Invest and High-Tech Gründerfonds.  Akribion is developing an RNA-guided,… Read More

#Business & Investment #Cancer Research #News #Start-up Zone

#Beacon Therapeutics #Dry AMD #Seed funding #Syncona

Beacon Therapeutics raises $170 million in a Series B financing 

Life science investors Syncona have committed $42.5 million to Beacon Therapeutics’ $170 million Series B financing round, bringing the total amount that Beacon has raised in funding to date to approximately $290 million. The funds will be used to support the continued clinical development of AGTC-501 for X-linked retinitis pigmentosa… Read More

#Business & Investment #News

#Cancer research #Clinical trials #Funding #iOnctura #Non-small cell lung cancer (NSCLC) #Seed funding

iOnctura announces €80m to progress pipeline  

iOnctura has closed an €80 million Series B financing to continue developing a portfolio of precision oral small molecules that target cancers in novel ways.   The funding round was led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council… Read More

#Business & Investment #Cancer Research #News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The ongoing innovation and development in the drug discovery sector relies on a number… Read More

#News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

This week in drug discovery (29 April – 3 May) 

News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More

#News

Seed fund
#Biologics #Seed funding #Start-ups #University of Dundee

Dundee spin-out raises £4m to advance VLPs

Glen Clova Scientific has closed a £4 million (approximately $5 million) seed financing round, led by Norcliffe Capital together with investment from DSW Ventures, TRICAPITAL Angels and Scottish Enterprise. Glen Clova Scientific was founded in 2022 as a spin out from the University of Dundee to… Read More

#News #Start-up Zone

#Antibodies #Artificial intelligence (AI) #Biologics #Investment #Seed funding #Start-ups

AI drug discovery company Xaira launches with $1b investment

Xaira Therapeutics, a joint incubation by ARCH Venture Partners and Foresite Labs, has launched with more than $1 billion of committed capital from lead investors. Xaira is building a platform for drug discovery and development that it hopes will advance multiple drug programmes and unlock biological… Read More

#News #Start-up Zone #Trending News